HC Wainwright & Co. Assumes MiNK Therapeutics at Buy, Announces Price Target of $38
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsInitiationPrice Target
HC Wainwright & Co. analyst Matthew Keller assumes MiNK Therapeutics (NASDAQ:INKT) with a Buy rating and announces Price Target of $38.
HC Wainwright & Co. analyst Matthew Keller assumes MiNK Therapeutics (NASDAQ:INKT) with a Buy rating and announces Price Target of $38.